Roche announced that it has completed its previously announced acquisition of point-of-care (POC) technology firm LumiraDX.
The acquisition adds a platform that can run a wide range of immunoassay and clinical chemistry tests on a single instrument to Roche's diagnostics portfolio, with the potential for the firm to expand further into molecular testing, Roche said in a statement. The acquisition, which was completed following the receipt of all required antitrust and regulatory clearances, was signed at the end of 2023 for approximately $350 million.
The POC technology will complement Roche's diagnostics portfolio across clinical chemistry, immunochemistry, coagulation, and molecular testing, as well as across multiple disease areas, the firm said. Roche intends to use the platform's molecular diagnostics capabilities in its partnership with the Bill & Melinda Gates Foundation to develop a rapid POC molecular tuberculosis test.
